Literature DB >> 29304541

Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE).

Behnood Bikdeli1,2, David Jimenez3, Mayra Hawkins4, Salvador Ortíz5, Paolo Prandoni6, Benjamin Brenner7, Hervé Decousus8, Frederick A Masoudi9, Javier Trujillo-Santos10, Harlan M Krumholz2,11, Manuel Monreal12.   

Abstract

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a preventable cause of in-hospital death, and one of the most prevalent vascular diseases. There is a lack of knowledge with regards to contemporary presentation, management and outcomes of patients with VTE. Many clinically important subgroups (including the elderly, those with recent bleeding and pregnant patients) have been under-represented in clinical trials. Furthermore, design of clinical trials is challenging in some scenarios, such as in those with hemodynamically unstable PE. RIETE (Registro Informatizado Enfermedad TromboEmbolica) is a large prospective multinational ongoing registry, designed to address these unmet needs using representative data from multiple centres. Initiated in Spain in 2001, RIETE currently includes 179 centres in 24 countries and has enrolled more than 72,000 patients. RIETE has helped characterize the pattern of presentation and outcomes of VTE, including the aforementioned understudied subgroups. RIETE has recently expanded to collect long-term outcome data, and has broadened its inclusion criteria to enrol other forms of venous thrombosis (such as cerebral vein thrombosis and splanchnic vein thrombosis). The RIETE platform is also being used to conduct pragmatic comparative effectiveness studies, including randomized trials. Future steps would focus on collaboration with additional centres across the world, and efforts to ensure the quality and expansion of the registry. In conclusion, RIETE is a large ongoing registry of patients with VTE and other thrombotic conditions. Its results could be helpful for improving our understanding of the epidemiology, patterns of care and outcomes of patients with thrombotic disease. Schattauer GmbH Stuttgart.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29304541      PMCID: PMC5821113          DOI: 10.1160/TH17-07-0511

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  41 in total

1.  The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association.

Authors:  Vincent J Bufalino; Frederick A Masoudi; Steven K Stranne; Katie Horton; Nancy M Albert; Craig Beam; Robert O Bonow; Roger L Vern Davenport; Meighan Girgus; Gregg C Fonarow; Harlan M Krumholz; Mark W Legnini; William R Lewis; Graham Nichol; Eric D Peterson; John S Rumsfeld; Lee H Schwamm; David M Shahian; John A Spertus; Pamela K Woodard; Clyde W Yancy
Journal:  Circulation       Date:  2011-04-11       Impact factor: 29.690

2.  Venous thromboembolism in patients with intracranial haemorrhage.

Authors:  José Luís Lobo; José Antonio Nieto; Vanesa Zorrilla; Noelia Garrido; Olga Madridano; Justo Ruiz; Dominique Farge-Bancel; Gregorio Tiberio; Fernando Uresandi; Manuel Monreal
Journal:  Thromb Haemost       Date:  2011-09-08       Impact factor: 5.249

3.  Real-World Evidence - What Is It and What Can It Tell Us?

Authors:  Rachel E Sherman; Steven A Anderson; Gerald J Dal Pan; Gerry W Gray; Thomas Gross; Nina L Hunter; Lisa LaVange; Danica Marinac-Dabic; Peter W Marks; Melissa A Robb; Jeffrey Shuren; Robert Temple; Janet Woodcock; Lilly Q Yue; Robert M Califf
Journal:  N Engl J Med       Date:  2016-12-08       Impact factor: 91.245

4.  Clinical outcome of patients with venous thromboembolism and recent major bleeding: findings from a prospective registry (RIETE).

Authors:  J A Nieto; A D De Tuesta; P J Marchena; G Tiberio; J A Todoli; A L Samperiz; M Monreal
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

5.  Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function.

Authors:  Javier Trujillo-Santos; Sebastian Schellong; Conxita Falga; Vanessa Zorrilla; Pedro Gallego; Manuel Barrón; Manuel Monreal
Journal:  Am J Med       Date:  2013-03-14       Impact factor: 4.965

6.  Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry.

Authors:  Silvy Laporte; Patrick Mismetti; Hervé Décousus; Fernando Uresandi; Remedios Otero; Jose Luis Lobo; Manuel Monreal
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

Review 7.  Global Burden of Thrombosis: Epidemiologic Aspects.

Authors:  Aaron M Wendelboe; Gary E Raskob
Journal:  Circ Res       Date:  2016-04-29       Impact factor: 17.367

8.  Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTEval Project.

Authors:  Bernd Frank; Liana Ariza; Heidrun Lamparter; Vera Grossmann; Jürgen H Prochaska; Alexander Ullmann; Florentina Kindler; Gerhard Weisser; Ulrich Walter; Karl J Lackner; Christine Espinola-Klein; Thomas Münzel; Stavros V Konstantinides; Philipp S Wild
Journal:  BMJ Open       Date:  2015-07-01       Impact factor: 2.692

9.  VTE Registry: What Can Be Learned from RIETE?

Authors:  Inna Tzoran; Benjamin Brenner; Manolis Papadakis; Pierpaolo Di Micco; Manuel Monreal
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

10.  The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry.

Authors:  Giancarlo Agnelli; Anselm K Gitt; Rupert Bauersachs; Eva-Maria Fronk; Petra Laeis; Patrick Mismetti; Manuel Monreal; Stefan N Willich; Wolf-Peter Wolf; Alexander T Cohen
Journal:  Thromb J       Date:  2015-10-21
View more
  36 in total

1.  Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry).

Authors:  Reza Mirza; Robby Nieuwlaat; Juan J López-Núñez; Raquel Barba; Arnav Agarwal; Carme Font; Maurizio Ciammaichella; Elvira Grandone; Rick Ikesaka; Mark Crowther; Manuel Monreal
Journal:  Blood Adv       Date:  2020-06-09

2.  Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry.

Authors:  Ido Weinberg; Jay Giri; Raghu Kolluri; Juan Ignacio Arcelus; Conxita Falgá; Silvia Soler; Andrei Braester; José Bascuñana; Javier Gutiérrez-Guisado; Manuel Monreal
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

3.  Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis.

Authors:  Behnood Bikdeli; Babak Sharif-Kashani; Bavand Bikdeli; Reina Valle; Conxita Falga; Antoni Riera-Mestre; Lucia Mazzolai; Peter Verhamme; Philip S Wells; Juan Francisco Sánchez Muñoz Torrero; Luciano Lopez-Jiménez; Manuel Monreal
Journal:  Semin Thromb Hemost       Date:  2018-01-12       Impact factor: 4.180

4.  Management of isolated distal deep-vein thrombosis with direct oral anticoagulants in the RIETE registry.

Authors:  Jean-Philippe Galanaud; Javier Trujillo-Santos; Behnood Bikdeli; Pierpaolo Di Micco; Cristiano Bortoluzzi; Laurent Bertoletti; José María Pedrajas; Aitor Ballaz; Joaquín Alfonso; Manuel Monreal
Journal:  J Thromb Thrombolysis       Date:  2020-11-28       Impact factor: 2.300

5.  Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism.

Authors:  Meritxell Mellado; Javier Trujillo-Santos; Behnood Bikdeli; David Jiménez; Manuel Jesús Núñez; Martin Ellis; Pablo Javier Marchena; Jerónimo Ramón Vela; Albert Clara; Farès Moustafa; Manuel Monreal
Journal:  Intern Emerg Med       Date:  2019-05-03       Impact factor: 3.397

6.  Clinical characteristics and outcomes of venous thromboembolic events after hallux valgus surgery: insights from the RIETE registry.

Authors:  Bavand Bikdeli; Renuka Visvanathan; Ido Weinberg; Agustina Rivas; José Antonio Nieto; Ángel Sampériz; Mónica Loring; Fernando Javier Vázquez; Hugo Hyung Bok Yoo; Behnood Bikdeli; Manuel Monreal
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

7.  Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology).

Authors:  J Muñoz-Langa; P Jimenez-Fonseca; A Carmona-Bayonas; E M de Castro; P Pérez-Segura; M S Cánovas; D Gomez; L O Moran; M B G de Tejada; E Seguí; G B López; S G Adrián; M C Campos; V P Olmos; B O Portero; M S Moyano; J A S Crespo; L T Sánchez; M A Rebollo; P O Rivas; J P Altozano; Á R Lescure; A Muñoz-Martín
Journal:  Clin Transl Oncol       Date:  2020-08-13       Impact factor: 3.405

8.  Predicting the risk for major bleeding in elderly patients with venous thromboembolism using the Charlson index. Findings from the RIETE.

Authors:  Covadonga Gómez-Cuervo; Agustina Rivas; Adriana Visonà; Nuria Ruiz-Giménez; Ángeles Blanco-Molina; Inmaculada Cañas; José Portillo; Patricia López-Miguel; Katia Flores; Manuel Monreal
Journal:  J Thromb Thrombolysis       Date:  2020-09-18       Impact factor: 2.300

9.  Clinical characteristics, time course, and outcomes of major bleeding according to bleeding site in patients with venous thromboembolism.

Authors:  Behnood Bikdeli; Fares Moustafa; José Antonio Nieto; Alfred I Lee; Nuria Ruíz-Giménez; Alicia Lorenzo; Sebastian Schellong; Silvia Soler; Salvador Ortíz; Mª Del Valle Morales; Marijan Bosevski; Olga Gavín; Gregory Y H Lip; Manuel Monreal
Journal:  Thromb Res       Date:  2022-01-14       Impact factor: 3.944

10.  Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis.

Authors:  Pablo Demelo-Rodriguez; Ana Isabel Farfán-Sedano; José María Pedrajas; Pilar Llamas; Patricia Sigüenza; María Jesús Jaras; Manuel Quintana-Diaz; Carmen Fernández-Capitán; Behnood Bikdeli; David Jiménez; Manuel Monreal
Journal:  J Thromb Haemost       Date:  2021-06-20       Impact factor: 16.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.